$13.18
0.01[0.08%]
At close: May 15
$13.18
0[0.00%]
PreMarket: 4:07PM EDT
OptimizeRx
(NASDAQ:OPRX)OptimizeRx Stock (NASDAQ:OPRX), Analyst Ratings, Price Targets, Predictions
OptimizeRx Corp has a consensus price target of $25.45, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from JMP Securities, Stifel, and JMP Securities on May 15, 2024, May 15, 2024, and April 16, 2024. With an average price target of $14.67 between JMP Securities, Stifel, and JMP Securities, there's an implied 11.28% upside for OptimizeRx Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Stifel
RBC Capital
Barclays
Lake Street
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for OptimizeRx
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/15/2024 | Buy Now | 21.4% | JMP Securities | Constantine Davides | $15 → $16 | Maintains | Market Outperform | Get Alert |
| 05/15/2024 | Buy Now | -1.37% | Stifel | David Grossman | $13 → $13 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 13.81% | JMP Securities | Constantine Davides | → $15 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/04/2024 | Buy Now | 13.81% | JMP Securities | Constantine Davides | → $15 | Initiates | → Market Outperform | Get Alert |
| 04/01/2024 | Buy Now | -1.37% | Stifel | David Grossman | $13 → $13 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | 28.98% | RBC Capital | Sean Dodge | → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 01/10/2024 | Buy Now | 28.98% | RBC Capital | Sean Dodge | $14 → $17 | Maintains | Outperform | Get Alert |
| 01/03/2024 | Buy Now | 13.81% | Barclays | Stephanie Davis | → $15 | Initiates | → Equal-Weight | Get Alert |
| 08/15/2023 | Buy Now | 6.22% | RBC Capital | Sean Dodge | $18 → $14 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | -1.37% | Lake Street | Eric Martinuzzi | $18 → $13 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 51.75% | Roth MKM | Richard Baldry | $31 → $20 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 36.57% | B. Riley Securities | Neil Chatterji | $28 → $18 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | -1.37% | Stifel | David Grossman | $16 → $13 | Maintains | Buy | Get Alert |
| 03/09/2023 | Buy Now | 36.57% | RBC Capital | Sean Dodge | $22 → $18 | Maintains | Outperform | Get Alert |
| 02/02/2023 | Buy Now | 127.62% | B. Riley Securities | Neil Chatterji | → $30 | Reinstates | → Buy | Get Alert |
| 11/01/2022 | Buy Now | 44.16% | Stifel | David Grossman | → $19 | Initiates | → Buy | Get Alert |
| 10/31/2022 | Buy Now | 44.16% | Stifel | David Grossman | → $19 | Initiates | → Buy | Get Alert |
| 08/10/2022 | Buy Now | 66.92% | RBC Capital | Sean Dodge | $50 → $22 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 21.4% | Piper Sandler | Jeff Garro | $29 → $16 | Maintains | Neutral | Get Alert |
| 08/10/2022 | Buy Now | 127.62% | SVB Leerink | Joy Zhang | $38 → $30 | Maintains | Outperform | Get Alert |
| 07/20/2022 | Buy Now | 324.89% | B. Riley Securities | Marc Wiesenberger | $71 → $56 | Maintains | Buy | Get Alert |
| 07/15/2022 | Buy Now | 188.32% | SVB Leerink | Joy Zhang | → $38 | Initiates | → Outperform | Get Alert |
| 07/01/2022 | Buy Now | 120.03% | Piper Sandler | Jeff Garro | → $29 | Initiates | → Neutral | Get Alert |
| 05/05/2022 | Buy Now | 279.36% | RBC Capital | Sean Dodge | $100 → $50 | Maintains | Outperform | Get Alert |
| 05/05/2022 | Buy Now | 400.76% | Roth Capital | Richard Baldry | $112 → $66 | Maintains | Buy | Get Alert |
| 02/16/2022 | Buy Now | 476.63% | Lake Street | Eric Martinuzzi | $98 → $76 | Maintains | Buy | Get Alert |
| 11/10/2021 | Buy Now | 658.73% | RBC Capital | Sean Dodge | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for OptimizeRx (OPRX)?
The latest price target for OptimizeRx (NASDAQ: OPRX) was reported by JMP Securities on May 15, 2024. The analyst firm set a price target for $16.00 expecting OPRX to rise to within 12 months (a possible 21.40% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for OptimizeRx (OPRX)?
The latest analyst rating for OptimizeRx (NASDAQ: OPRX) was provided by JMP Securities, and OptimizeRx maintained their market outperform rating.
When was the last upgrade for OptimizeRx (OPRX)?
There is no last upgrade for OptimizeRx.
When was the last downgrade for OptimizeRx (OPRX)?
There is no last downgrade for OptimizeRx.
When is the next analyst rating going to be posted or updated for OptimizeRx (OPRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OptimizeRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OptimizeRx was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.
Is the Analyst Rating OptimizeRx (OPRX) correct?
While ratings are subjective and will change, the latest OptimizeRx (OPRX) rating was a maintained with a price target of $15.00 to $16.00. The current price OptimizeRx (OPRX) is trading at is $13.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.